By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Apogenix 

Im Neuenheimer Feld 584

Heidelberg    69120  Germany
Phone: 49-0-6221-58608-0 Fax: 49-0-6221-58608-10


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Delivery





Company News
Apogenix- Positive Results From APG101 Phase 2 Clinical Trial Published In Clinical Cancer Research 10/28/2014 7:56:05 AM
Apogenix' APG101 Demonstrates Significant Prolongation Of Overall Survival In Biomarker-Positive Patients In Phase II Trial For The Treatment Of Recurrent Glioblastoma 1/13/2014 9:23:17 AM
Apogenix To Present Phase II Results With APG101 For The Treatment Of Recurrent Glioblastoma At Biotech Showcase In San Francisco 1/7/2014 8:10:09 AM
Apogenix' APG350 Effectively Induces Apoptosis Of Tumor Cells Via TRAIL Pathway Independent Of Fc-gamma Cross-Linking 12/5/2013 9:28:16 AM
Apogenix Strengthens Patent Position for Apocept™ (APG101) in Europe and Canada 7/2/2013 10:00:36 AM
Apogenix Receives FDA Orphan Drug Designation for Apocept™ to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study 2/7/2013 10:18:04 AM
Apogenix's Apocept™ for Glioblastoma Multiforme Named One of "Top 10 Projects to Watch" 11/6/2012 1:54:00 PM
Apogenix: APG101 Exceeds Expectations With Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma 7/26/2012 10:01:36 AM
Apogenix Receives Additional €2.3 Million BMBF Grant as Partner of the Biotech Cluster Rhine-Neckar 1/9/2012 2:40:12 PM
Apogenix Raises €7.5 Million to Further Advance APG101 to Treat Glioblastoma and Other Tumors 1/5/2012 9:26:04 AM
12
//-->